Health News

Vertex Pharmaceuticals Incorporated announced today that 15 abstracts on the company’s medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver in Berlin, Germany, March 30 to April 3, 2011.

Read more

Filed under: Pharmacy News
Tags: Hepatitis, medicine, Pharmacy

Related posts

• Study demonstrates possibility of curing hepatitis C without use of interferon (0)
  Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders'). Read more [tags] Pharmacy News [/tags]
  
  
• Study demonstrates possibility of curing hepatitis C without use of interferon (0)
  Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders'). Read more [tags] Pharmacy News [/tags]
  
  
• Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients (0)
  Treatment with a telaprevir-based combination regimen for hepatitis C - heretofore a chronic, destructive and difficult to manage disease - effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine. Read more [tags] Pharmacy News [/tags]
  
  
• Patients with hepatitis C may benefit from 24 week telaprevir-based regimen (0)
  University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured. Read more [tags] Pharmacy News [/tags]
  
  
• Patients with chronic hepatitis C less likely to take medications over time (0)
  Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania. Read more [tags] Pharmacy News [/tags]